LIBTAYO J Code: J9119

Drug & Product Overview

HCPCS Descriptor Injection, cemiplimab-rwlc, 1 mg

HCPCS Added Date October 1, 2019

Manufacturer Regeneron Pharmaceuticals, Inc

Route of Administration Intravenous

Generic Status Single-Source; Branded

Dosage Type Single-Dose

Dosage Form Injection

About LIBTAYO

Libtayo is a medication aligned to the HCPCS J Code: J9119 for billing, pricing, and reimbursement purposes in the United States. Classified under Oncology, it is administered via the intravenous route and manufactured by Regeneron Pharmaceuticals, Inc.

According to CMS Drug Use Information: Cemiplimab is used to treat certain types of cancer (such as skin, lung). It works by changing the action of your own immune system, directing it to attack cancer cells. Cemiplimab belongs to a class of drugs known as monoclonal antibodies.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
61755-0008-01	Libtayo	Regeneron Pharmaceuticals, Inc.	350	350 MG / 7 ML

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

LIBTAYO Pricing & Reimbursement

J9119 Private Payer Reimbursement

$29.76 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q3 2026

LIBTAYO Claims Performance

Claims from Jan 2026 – Aug 2026

Claim Denial Rate 8.53%

Avg. Days to File 7.0days

Avg. Days to Pay 23.0days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore J9119 claims analytics on FocalPoint →

LIBTAYO CPT Administration Codes

CPT Code	Description
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415	Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)

JW / JZ modifiers apply

CMS has identified Libtayo (J9119) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. Wastage billing guide →

LIBTAYO Medically Unlikely Edits (MUE)

The most billing units of J9119 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 1 mg.

Practitioner Office & Hospital Outpatient

700 units / day

= 700 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

LIBTAYO Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Basal Cell Carcinoma Cutaneous Squamous Cell Carcinoma Non-Small Cell Lung Cancer

Frequently Asked Questions

Is there an available Libtayo billing and coding guide?

Billing and coding information for LIBTAYO can be found through Regeneron. Visit Here →

Are there any available Libtayo patient assistance programs?

LIBTAYO patient assistance information can be found through Regeneron. Visit Here →

Where can I find Libtayo prescribing information?

LIBTAYO prescribing information can be found at the link below: Visit Here →

Where can I find Libtayo side effect information?

Information regarding LIBTAYO's side effects can be found at MedlinePlus Visit Here →

Does billing LIBTAYO require JZ/JW wastage modifiers?

CMS has identified LIBTAYO(J9119) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. See CMS guidelines on use of the JZ and JW wastage modifiers below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.